Sk2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SK2 is a small-conductance calcium-activated potassium channel highly expressed in hippocampus. It plays critical roles in synaptic plasticity, learning, and memory. SK2 is localized to dendritic spines and regulates synaptic integration. [1]
SK2 Protein is encoded by the KCNN2 gene. It is a Small conductance calcium-activated potassium channel. The UniProt ID is Q9H5Y2. [2]
--- [3]
SK2 is a small-conductance calcium-activated potassium channel highly expressed in hippocampus. It plays critical roles in synaptic plasticity, learning, and memory. SK2 is localized to dendritic spines and regulates synaptic integration. [4]
The protein is expressed in Plasma membrane, Postsynaptic density and plays important roles in cellular physiology. [5]
--- [6]
SK2 mutations cause epilepsy and ataxia. SK2 dysfunction contributes to cognitive deficits in Alzheimer's disease. [7]
SK2 is a target for nootropic drugs. Apamin and related compounds are specific SK channel blockers.
The study of Sk2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
KCNN channels (SK/IK): Stocker M. Nat Rev Neurosci. KCNN channels (SK/IK). 2004. ↩︎
KCa channels in neurodegeneration: Shah NH, et al. Nat Rev Neurosci. KCa channels in neurodegeneration. 2018. ↩︎
Potassium channel dysfunction in AD: Angulo E, et al. J Neurosci. Potassium channel dysfunction in AD. 2004. ↩︎
Potassium channels and neuronal excitability: Bean BP. Nat Rev Neurosci. Potassium channels and neuronal excitability. 2007. ↩︎
SK channel activators as therapy: Ehling P, et al. Nat Rev Drug Discov. SK channel activators as therapy. 2020. ↩︎
Potassium channels in PD: Lüscher C, Slesinger PA. Nat Rev Neurosci. Potassium channels in PD. 2010. ↩︎
Ion channel therapeutics: Garnock-Jones KP. CNS Drugs. Ion channel therapeutics. 2017. ↩︎